{"id":6227,"date":"2023-05-05T10:00:00","date_gmt":"2023-05-05T10:00:00","guid":{"rendered":"https:\/\/modernsciences.org\/staging\/4414\/?p=6227"},"modified":"2023-04-20T06:57:20","modified_gmt":"2023-04-20T06:57:20","slug":"scientists-develop-device-to-deliver-immunotherapy-directly-to-pancreatic-tumors","status":"publish","type":"post","link":"https:\/\/modernsciences.org\/staging\/4414\/scientists-develop-device-to-deliver-immunotherapy-directly-to-pancreatic-tumors\/","title":{"rendered":"Scientists Develop Device to Deliver Immunotherapy Directly to Pancreatic Tumors"},"content":{"rendered":"\n

Scientists at Houston Methodist Research Institute<\/a> have developed an implantable device that delivers immunotherapy directly to pancreatic tumors. In a study published in Advanced Science<\/em><\/a>, researchers used the nanofluidic drug-eluting seed (NDES) device to deliver CD40 monoclonal antibodies (mAb), a promising immunotherapeutic agent, to murine models. The NDES device, smaller than a grain of rice, delivered a sustained low dose of immunotherapy, resulting in a fourfold reduction in tumor size compared to traditional systemic immunotherapy treatment.<\/p>\n\n\n

\n
\"\"
(\u201cPancreatic Cancer Cells<\/a>\u201d by National Institutes of Health (NIH)<\/a> is licensed under CC BY-NC 2.0<\/a>.)<\/figcaption><\/figure>\n<\/div>\n\n\n

The NDES device consists of a stainless-steel drug reservoir containing nanochannels that create a membrane, allowing for sustained diffusion when the drug is released. The delivery of the immunotherapy directly into the tumor allows for a more focused therapy with fewer side effects, leading to a better quality of life for patients undergoing treatment. One animal model remained tumor-free for 100 days of continuous observation, and the technology is being studied in a similar capacity on the International Space Station<\/a>.<\/p>\n\n\n\n

Pancreatic ductal adenocarcinoma is frequently diagnosed at advanced stages, with about 85% of patients already having the metastatic disease at diagnosis. Houston Methodist researchers are studying the effectiveness and safety of this delivery technology, hoping to see it become a viable option for cancer patients within the next five years. The researchers are also conducting additional lab research to determine the long-term effectiveness and safety of the NDES device, which is intended for long-term controlled and sustained release, avoiding repeated systemic treatment that often leads to adverse side effects.<\/p>\n\n\n\n

References<\/h1>\n\n\n\n